Related Experiment Video
Updated: May 14, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis
T Gamucci1, A Vaccaro, F Ciancola
1Medical Oncology Unit, ASL Frosinone, Via Armando Fabi, 03100 Frosinone, Italy.
Journal of Cancer Research and Clinical Oncology
|February 16, 2013
Summary
Small node-negative breast cancer patients have favorable outcomes, but Her-2 positive and triple-negative subtypes show higher recurrence risks. Chemotherapy may benefit patients with pT1b/c tumors in these higher-risk groups.
Area of Science:
- Oncology
- Breast Cancer Research
- Clinical Trials
Background:
- Adjuvant treatment decisions for small, node-negative breast cancer remain challenging.
- Understanding recurrence risk factors is crucial for personalized treatment strategies.
Purpose of the Study:
- To evaluate recurrence risk in node-negative breast cancer patients (pT1a, b, c).
- To analyze risk based on prognostic biological factors and tumor subtypes.
Main Methods:
- Retrospective analysis of 900 node-negative patients (pT1a, b, c) treated between 2000-2009.
- Categorization into Estrogen Receptor-positive (ER+), HER2-positive (Her-2+), and Triple-Negative (TN) cohorts.
Main Results:
- 5-year Disease-Free Survival (DFS) was generally favorable (96.3% overall).
- Her-2+ and TN cohorts exhibited higher recurrence rates compared to ER+.
- Histologic grade and Ki-67 were identified as independent prognostic factors.
Conclusions:
- Small node-negative breast cancers show favorable DFS, but Her-2+ and TN subtypes have increased recurrence risk.
- Patients with pT1b/c tumors in Her-2+ and TN subgroups may benefit from chemotherapy.
- Further investigation into tailored adjuvant therapies for high-risk subgroups is warranted.
